Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial.
Thomas VanasschePeter VerhammeSonia S AnandOlga ShestakovskaDarryl P LeongKeith A A FoxDeepak L BhattÁlvaro AvezumMarco AlingsVictor AboyansAldo P MaggioniPetr WidimskyEva MuehlhoferScott D BerkowitzSalim YusufStuart J ConnollyJohn William EikelboomJacqueline BoschPublished in: European heart journal. Cardiovascular pharmacotherapy (2021)
Adding low-dose rivaroxaban to aspirin resulted in benefits irrespective of the number of concomitant drugs or comorbidities. Multiple comorbidities and/or polypharmacy should not dissuade the addition of rivaroxaban to aspirin in otherwise eligible patients.
Keyphrases
- low dose
- venous thromboembolism
- atrial fibrillation
- high dose
- pulmonary embolism
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- cardiovascular events
- clinical trial
- peritoneal dialysis
- emergency department
- type diabetes
- cardiovascular disease
- phase iii
- adverse drug
- coronary artery disease
- patient reported
- open label